Legal & General Group’s Strata Critical Medical Inc SRTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24.4K Hold
5,833
﹤0.01% 2900
2025
Q4
$28.1K Hold
5,833
﹤0.01% 2900
2025
Q3
$29.5K Hold
5,833
﹤0.01% 2894
2025
Q2
$23.5K Buy
5,833
+1,097
+23% +$3.57K ﹤0.01% 2941
2025
Q1
$12.9K Hold
4,736
﹤0.01% 3096
2024
Q4
$20.1K Hold
4,736
﹤0.01% 3018
2024
Q3
$13.9K Hold
4,736
﹤0.01% 3180
2024
Q2
$16.5K Hold
4,736
﹤0.01% 3103
2024
Q1
$13.5K Hold
4,736
﹤0.01% 3130
2023
Q4
$16.7K Hold
4,736
﹤0.01% 3103
2023
Q3
$12.3K Sell
4,736
-975
-17% -$3.42K ﹤0.01% 3226
2023
Q2
$22.5K Sell
5,711
-1,992
-26% -$6.32K ﹤0.01% 3073
2023
Q1
$26K Hold
7,703
﹤0.01% 2996
2022
Q4
$27.6K Sell
7,703
-10,663
-58% -$45.6K ﹤0.01% 3080
2022
Q3
$74K Sell
18,366
-717
-4% -$3.68K ﹤0.01% 2893
2022
Q2
$85K Buy
+19,083
New +$138K ﹤0.01% 2896

Other funds holding SRTA

Legal & General Group's SRTA Position: Q1 2026 in Review

Legal & General Group held its Strata Critical Medical Inc (SRTA) position steady in Q1 2026 at 5,833 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2900.

Legal & General Group first reported a position in SRTA in Q2 2022 and has held it in 16 quarters since. The position peaked at $85K in Q2 2022. 125 funds tracked by Wall St. Rank hold SRTA as of Q1 2026.

  • Legal & General Group held 5,833 shares of Strata Critical Medical Inc worth $24.4K as of Q1 2026.
  • Legal & General Group left its Strata Critical Medical Inc share count unchanged in Q1 2026.
  • Strata Critical Medical Inc made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2900 holding.
  • Legal & General Group first reported a position in Strata Critical Medical Inc in Q2 2022 and has held it in 16 quarters since.
  • Legal & General Group's Strata Critical Medical Inc position peaked at $85K in Q2 2022.
  • 125 funds tracked by Wall St. Rank held Strata Critical Medical Inc as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.